Evidence from evidence-based medicine supports that early high-risk patients should be treated with chemotherapy, while low-risk patients do not benefit from chemotherapy. According to the evidence level of evidence-based medicine, the 2013 edition of the NCCN guidelines in the United States recommends that patients with stage Ia or Ib G1 can be treated without chemotherapy; patients with stage Ia and Ib G2 can be considered for both 3-6 courses of chemotherapy and observation; all other early-stage patients need chemotherapy. The guidelines of the Chinese Medical Association Gynecologic Oncology Society for the diagnosis and treatment of ovarian cancer recommend that all epithelial carcinomas should be treated with chemotherapy except for those with IaG1. The current domestic consensus is that stage I ovarian cancer should be treated with chemotherapy as long as it has more than 1 of the following high-risk factors: 1. no precise surgical staging; 2. histologically poor prognosis type, such as clear cell carcinoma and metastatic cell carcinoma; 3. medium or low differentiated tumor; 4. stage Ic (surface papillae, rupture or incomplete envelope, positive cytology of ascites or peritoneal washings); 5. adhesions around the tumor; 6. , DNA ploidy analysis of tumor cells was non-diploid.